PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:
G01N 33/68, C07K 7/06, 7/08
A1
(11) International Publication Number: WO 98/49561
(43) International Publication Date: 5 November 1998 (05.11.98)

(21) International Application Number:

mber: PCT/GB98/01238

(22) International Filing Date:

28 April 1998 (28.04.98)

(30) Priority Data:

9708676.3

30 April 1997 (30.04.97)

GB

(71) Applicant (for all designated States except US): IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED [GB/GB]; Sardinia House, Sardinia Street, London WC2A 3NL (GB).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): HEERY, David, Michael [IE/GB]; Imperial Cancer Research Fund, Molecular Endocrinology Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX (GB). PARKER, Malcolm, George [GB/GB]; Imperial Cancer Research Fund, Molecular Endocrinology Laboratory, 44 Lincoln's Inn Fields, London WC2A 3PX (GB).
- (74) Agent: GILES, Allen, Frank; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Tide: INHIBITORS OF NUCLEAR PROTEIN/NUCLEAR RECEPTOR INTERACTION

(57) Abstract

A method for identifying inhibitor compounds capable of reducing the interaction between a first region which is a signature motif on a nuclear protein, and a second region which is that part of a nuclear receptor which is capable of interacting with the nuclear protein through binding to the signature motif, wherein: the nuclear protein is a bridging factor that is responsible for the interaction between a liganded nuclear receptor and a transcription initiation complex involved in regulation of gene expression; the nuclear receptor is a transcription factor, the signature motif is a short sequence of amino acid residues which is the key structural element of a nuclear protein which binds to a liganded nuclear receptor as part of the process of the activation or repression of target genes.